JP6110817B2 - 大環状キナーゼ阻害剤の固体形態 - Google Patents

大環状キナーゼ阻害剤の固体形態 Download PDF

Info

Publication number
JP6110817B2
JP6110817B2 JP2014124999A JP2014124999A JP6110817B2 JP 6110817 B2 JP6110817 B2 JP 6110817B2 JP 2014124999 A JP2014124999 A JP 2014124999A JP 2014124999 A JP2014124999 A JP 2014124999A JP 6110817 B2 JP6110817 B2 JP 6110817B2
Authority
JP
Japan
Prior art keywords
ppm
crystalline
values
resonance
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014124999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015010091A5 (https=
JP2015010091A (ja
Inventor
ジェームス ジェンセン アンドリュー
ジェームス ジェンセン アンドリュー
ルスラ スマン
ルスラ スマン
フランシス リチャードソン ポール
フランシス リチャードソン ポール
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2015010091A publication Critical patent/JP2015010091A/ja
Publication of JP2015010091A5 publication Critical patent/JP2015010091A5/ja
Application granted granted Critical
Publication of JP6110817B2 publication Critical patent/JP6110817B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014124999A 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態 Expired - Fee Related JP6110817B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840703P 2013-06-28 2013-06-28
US61/840,703 2013-06-28

Publications (3)

Publication Number Publication Date
JP2015010091A JP2015010091A (ja) 2015-01-19
JP2015010091A5 JP2015010091A5 (https=) 2016-08-04
JP6110817B2 true JP6110817B2 (ja) 2017-04-05

Family

ID=51136530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014124999A Expired - Fee Related JP6110817B2 (ja) 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態

Country Status (8)

Country Link
US (1) US9637500B2 (https=)
EP (1) EP3013835B1 (https=)
JP (1) JP6110817B2 (https=)
AR (1) AR096759A1 (https=)
CA (1) CA2916605C (https=)
ES (1) ES2656189T3 (https=)
TW (1) TW201504246A (https=)
WO (1) WO2014207606A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10159663B2 (en) * 2014-08-20 2018-12-25 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
EP3798222B1 (en) 2015-07-31 2023-11-22 Pfizer Inc. Crystalline form of lorlatinib free base
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
EP3415518B1 (en) 2016-03-03 2020-07-08 Shenzhen TargetRx, Inc. Macrocycle and composition comprising thereof
EP3440086B1 (en) * 2016-04-08 2020-08-12 Pfizer Inc. Crystalline forms of lorlatinib maleate
JP7153069B2 (ja) 2017-10-10 2022-10-13 ファイザー・インク ロルラチニブ遊離塩基水和物の結晶形態
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US20210163498A1 (en) 2018-04-23 2021-06-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
US12077528B2 (en) 2018-11-28 2024-09-03 Shenzhen Targetrx, Inc. Preparation method for deuterated macrocyclic compound
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
EP3999514A1 (en) 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
CN112724077B (zh) * 2020-12-29 2023-07-11 武汉利昌医药科技有限公司 一种劳拉替尼中间体的合成方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases

Also Published As

Publication number Publication date
CA2916605A1 (en) 2014-12-31
EP3013835A1 (en) 2016-05-04
EP3013835B1 (en) 2017-12-13
WO2014207606A1 (en) 2014-12-31
US9637500B2 (en) 2017-05-02
AR096759A1 (es) 2016-02-03
TW201504246A (zh) 2015-02-01
CA2916605C (en) 2018-04-24
ES2656189T3 (es) 2018-02-26
JP2015010091A (ja) 2015-01-19
US20160115178A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
JP6110817B2 (ja) 大環状キナーゼ阻害剤の固体形態
KR102516745B1 (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
KR102088188B1 (ko) 롤라티닙 유리 염기의 결정질 형태
JP2024012540A (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
KR20210104808A (ko) Tgfb 억제제의 신규한 다형체 형태
CA3019905C (en) Crystalline forms of lorlatinib maleate
AU2016288209B2 (en) Crystalline fumarate salt of (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) (3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl)-methanone
KR20100085142A (ko) Ｃ-ｍｅｔ/ｈｇｆｒ 억제제의 다형체
JP2023502857A (ja) Ｌｒｒｋ２阻害薬としてのｎ－（ヘテロアリール）キナゾリン－２－アミン誘導体、医薬組成物及びその使用
JP2007277241A (ja) （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの多形体
EP4027999A1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
WO2024245364A1 (en) Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms
WO2024153249A1 (zh) 作为pkmyt1抑制剂的化合物
KR20260044269A (ko) 헌팅턴병 치료를 위한 스플라이싱 조절제인 6-(6-(((1r,2r,3s,5s)-2-플루오로-9-아자바이시클로[3.3.1]노난-3-일)(메틸)아미노)피리다진-3-일)-2-메틸벤조[d]옥사졸-5-올의 결정질 형태
TW202328152A (zh) 氮雜內醯胺化合物之晶型
CN120187724A (zh) 杂芳基衍生物化合物、及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170310

R150 Certificate of patent or registration of utility model

Ref document number: 6110817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees